Viamet Pharmaceuticals Secures $60,000,000 Series D Round

  • Feed Type
  • Date
    10/21/2014
  • Company Name
    Viamet Pharmaceuticals
  • Mailing Address
    4505 Emperor Blvd. Durham, NC 27703 USA
  • Company Description
    Viamet Pharmaceuticals discovers and develops best-in-class inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, our Metallophile Technology.
  • Website
    http://www.viamet.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $60,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    l compounds, as well as to initiate new research programs supported by the company’s Metallophile® platform. The financing is expected to provide sufficient capital to fund operations through the achievement of several important clinical milestones over the next number of years.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy